CTOs on the Move


 
febit is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.febit.com
  • 99 Hayden Ave
    Lexington, MA USA 02421
  • Phone: 781.391.4360

Executives

Name Title Contact Details

Similar Companies

Oncoceutics Pharmaceuticals Inc

Oncoceutics Pharmaceuticals Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Locus Fermentation Solutions

Locus Fermentation Solutions is the the accelerator company for Locus Agricultural Solutions and Locus Bio-Energy Solutions, LLC.

AnHeart Therapeutics

AnHeart is a clinical stage global biopharmaceutical company developing novel precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.

Eleven Therapeutics

Eleven Therapeutics is at the forefront of mRNA therapeutics innovation, harnessing combinatorial chemistry, synthetic biology, and artificial intelligence to develop next-generation therapies. The company`s pipeline includes extended-release mRNA therapeutics (xRNA) targeting unmet medical needs in metabolic, hematologic, and infectious disease areas. Proprietary high-throughput screening platforms, TERA™ and DELiveri™, underpin Eleven Therapeutics` pipeline by generating chemically modified xRNAs and cell-penetrating delivery carriers. Founded in 2020 by world-leading scientists across Cambridge (UK), Boston (US), and Tel Aviv (Israel), Eleven Therapeutics is supported by top-tier venture capitalists and the Bill & Melinda Gates Foundation.

X-Vax Technology

We`re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we`re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We`re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.